<DOC>
	<DOC>NCT01624974</DOC>
	<brief_summary>The purpose of this study is to evaluate the effect of MK-1029 on lung function in the treatment of adults who have persistent asthma that is uncontrolled with the use of montelukast (ML). Participants will use randomized study drug (either MK-1029 or placebo) for two separate 4-week treatment periods. All participants will also use ML during the treatment periods.</brief_summary>
	<brief_title>Study to Evaluate the Effectiveness and Safety of MK-1029 in the Treatment of Persistent Asthma That is Not Controlled With Montelukast (ML) in Adults (MK-1029-011 AM2)</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Montelukast</mesh_term>
	<criteria>not pregnant or breastfeeding and does not plan to become pregnant for the duration of the study; symptoms of persistent asthma for at least one year; current use of asthma treatments: 1) "asneeded" inhaled SABAs (albuterol/salbutamol) and no asthma controller for at least 4 weeks prior to Screening Visit OR 2) stable dose of ICS, combination ICS/LABA and/or oral asthma controller(s) for at least 4 weeks prior to Screening Visit and able to tolerate discontinuing all controllers while receiving ML; no history of smoking OR no smoking for at least 1 year, with a smoking history of no more than 10 packyears; able to maintain a constant day/night, awake/sleep cycle; agrees to not change habitual consumption of beverages or foods containing caffeine throughout the study; Body Mass Index (BMI) of 15 kg/m^2 to 40 kg/m^2. history of myocardial infarction, congestive heart failure, or uncontrolled cardiac arrhythmia within 3 months prior to Screening Visit; hospitalized or hospitalization within 4 weeks prior to Screening Visit; intention of moving or anticipation of missing any study visits; any major surgical procedure(s) within 4 weeks prior to Screening Visit; participation in a clinical trial involving an investigational drug within 4 weeks prior to Screening Visit; current regular use or a recent past abuse (within past 5 years) of alcohol (&gt;14 drinks/week) or illicit drugs; donation of a unit of blood within 2 weeks prior to Screening Visit or intention of donating a unit of blood during the study; evidence of another active pulmonary disorder such as bronchiectasis or COPD; treatment in an emergency room for asthma within 4 weeks prior to Screening Visit or hospitalization for asthma within 2 months prior to Screening Visit; respiratory tract infection which required treatment with antibiotics within 2 months prior to Screening Visit; evidence of active sinus disease within 1 week prior to Screening Visit; history of a psychiatric disorder, other than stable depression, within 3 months prior to Screening Visit; history of human immunodeficiency virus (HIV); hypersensitivity or intolerance to inhaled betaagonists and/or leukotriene inhibitors or any of their ingredients, including lactose and galactose; unstable disease of the ophthalmologic, neurological, hepatic, renal, connective tissue, genitourinary, gastrointestinal, cardiovascular or hematologic systems; cancer (except for successfully treated basal and squamous cell carcinomas of the skin) or history of cancer within 5 years prior to Screening Visit; uncontrolled hypertension.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>